Lupin launches Mycophenolic Acid Delayed-Release Tablets USP

06 Apr 2020 Evaluate
Lupin has launched Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and 360 mg. The company’s alliance partner Concord Biotech (Concord) had received an approval from the United States Food and Drug Administration (U.S. FDA) earlier.

Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and 360 mg, is the generic equivalent of Myfortic Delayed-Release Tablets, 180 mg and 360 mg, of Novartis Pharmaceuticals Corporation. This tablet is indicated for Prophylaxis of organ rejection in adult patients receiving kidney transplants and in pediatric patients at least 5 years of age and older who are at least 6 months post kidney transplant and use in combination with cyclosporine and corticosteroids.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2138.65 -12.40 (-0.58%)
01-Feb-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1610.20
Dr. Reddys Lab 1182.75
Cipla 1325.85
Zydus Lifesciences 878.80
Lupin 2138.65
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×